🧪 UPDATED DAILY FROM CLINICALTRIALS.GOVSynced Apr 1

Find Clinical Trials for Your Rare Disease

48+ recruiting trials across all rare diseases. Filter by phase, location, and condition.

Clinical trial records are synced from ClinicalTrials.gov.
Report missing data
Clear

Showing 20 of 48 recruiting trials for “immunoglobulin-a-nephropathy

RecruitingNCT07029542

Home Reported Outcomes in C3G Study

👨‍⚕️ Novartis Pharmaceuticals, Novartis Pharmaceuticals📍 1 site📅 Started Apr 2025View details ↗
RecruitingNCT06952426

A Mobile App-Based Study to Evaluate Disease Burden and Treatment Patterns in Immunoglobulin A Nephropathy (IgAN) in the US

🏥 Novartis Pharmaceuticals📍 1 site📅 Started Mar 2025View details ↗
Phase 2RecruitingNCT06797518

Study to Evaluate the Impact of Iptacopan on Top of SOC on Biopsy Changes in Kidneys of Adult Patients With IgAN

👨‍⚕️ Novartis Pharmaceuticals, Novartis Pharmaceuticals📍 16 sites📅 Started Feb 2025View details ↗
Phase 4RecruitingNCT06676384

Which of the Commonly Available and Approved Drugs in Addition to Standard of Care Can Significantly Improve the Slope of Estimated Glomerular Filtration Rate at Two Years When Compared to Standard of Care Alone in South-Asian Kidney Biopsy-proven Adult (≥18 Years) Primary IgA Nephropathy?

👨‍⚕️ Jonathan Barratt, PhD, FRCP, University of Leicester📍 12 sites📅 Started Feb 2025View details ↗
Phase 3RecruitingNCT06819826

A Study of SC0062 Capsule for the Treatment of IgA Nephropathy with Proteinuria

🏥 Biocity Biopharmaceutics Co., Ltd.📍 1 site📅 Started Feb 2025View details ↗
Phase 4RecruitingNCT06712407

Efficacy and Safety of Extended TARPEYO® Treatment Beyond 9 Months in Adult Patients With Primary IgA Nephropathy

👨‍⚕️ Krassimir Mitchev, Calliditas Therapeutics📍 38 sites📅 Started Dec 2024View details ↗
NARecruitingNCT06654596

Efficacy and Safety of Telitacicept in IgAN

🏥 Ruijin Hospital📍 1 site📅 Started Dec 2024View details ↗
Phase 2Enrolling by InvitationNCT06674577

A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Atacicept

👨‍⚕️ Zeeshan Khawaja, Vice President, Clinical Development📍 1 site📅 Started Dec 2024View details ↗
Phase 2RecruitingNCT06740526

Trial of the Impact of Sibeprenlimab on Immunoglobulin A Nephropathy Kidney Tissue

🏥 Otsuka Pharmaceutical Development & Commercialization, Inc.📍 5 sites📅 Started Nov 2024View details ↗
RecruitingNCT06676007

A Multi-center Open Label Prospective Study on Early Initiation of Targeted-release Formulation of Budesonide in Patients With Primary IgA Nephropathy

🏥 Sichuan Provincial People's Hospital📍 1 site📅 Started Oct 2024View details ↗
Phase 2RecruitingNCT06670352

Phase II Study of Efficacy and Safety of HSK39297 Tablet in Treatment of Patients with Primary IgAN

🏥 Haisco Pharmaceutical Group Co., Ltd.📍 2 sites📅 Started Oct 2024View details ↗
Phase 3RecruitingNCT06291376

Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)

🏥 Alexion Pharmaceuticals, Inc.📍 267 sites📅 Started Mar 2024View details ↗
Phase 3RecruitingNCT05510323

Efficacy of Immunosuppressive Therapy for IgA Nephropathy With Stage 3 or 4 CKD

🏥 Air Force Military Medical University, China📍 1 site📅 Started Feb 2024View details ↗
NARecruitingNCT06767592

A Study of Probiotics in IgA Nephropathy

🏥 University of Leicester📍 1 site📅 Started Oct 2023View details ↗
Phase 3RecruitingNCT05797610

A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression

👨‍⚕️ Clinical Trials, Hoffmann-La Roche📍 20 sites📅 Started Aug 2023View details ↗
Phase 1RecruitingNCT05942625

A First in Human Study to Evaluate Safety, Tolerability, Pharmacology of HS-10390 in Healthy Subjects

🏥 Hansoh BioMedical R&D Company📍 1 site📅 Started May 2023View details ↗
NARecruitingNCT05791162

Interest of Follicular Helper Lymphocytes / Regulatory Follicular Helper Lymphocytes Ratio in IgA Nephropathy

👨‍⚕️ Melchior Chabannes, MD, Nephrology, CHU Besançon📍 1 site📅 Started May 2023View details ↗
Phase 2RecruitingNCT05775042

Clinical Study of CM338 in the Treatment of Immunoglobulin A Nephropathy

👨‍⚕️ Jicheng Lv, Peking University First Hospital📍 1 site📅 Started May 2023View details ↗
Phase 4RecruitingNCT04662723

Multicentre Clinical Study to Evaluate the Effect of Personalized Therapy on Patients With Immunoglobulin A Nephropathy.

👨‍⚕️ Francesco P Schena, Fondazione Schena📍 2 sites📅 Started May 2023View details ↗
RecruitingNCT05434325

TESTING -ON Post-Trial ObservatioNal Cohort Study

👨‍⚕️ Hong Zhang, Prof, Peking University Institute of Nephrology📍 58 sites📅 Started Dec 2022View details ↗
← PreviousPage 2 of 3Next →

Get alerts when new trials open

Create a free account to follow conditions and receive trial notifications.

Create free account →